Skip to main content
Moleculin Biotech, Inc. logo

Moleculin Biotech, Inc. — Investor Relations & Filings

Ticker · MBRX ISIN · US60855D2009 LEI · 549300IB1TLJZCHEO353 US Manufacturing
Open in API
Filings indexed 784 across all filing types
Latest filing 2017-04-17 Regulatory Filings
Country US United States of America
Listing US MBRX

About Moleculin Biotech, Inc.

https://moleculin.com/

Moleculin Biotech, Inc. is a late-stage clinical pharmaceutical company focused on developing a portfolio of therapeutic candidates for highly resistant cancers and viruses. The company's lead drug candidate is Annamycin, a next-generation liposomal anthracycline designed to be non-cardiotoxic and to circumvent multidrug resistance. Annamycin is being advanced in a pivotal Phase 3 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company's development pipeline also includes other drug candidates targeting hard-to-treat tumors.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes the appointment of a contract research organization for a clinical trial and includes a press release as an exhibit. There are no financial statements or detailed financial data presented. The document length is 2574 characters, which is relatively short and primarily serves as an announcement rather than a full report. Therefore, it does not qualify as an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is also not a Management or Board change announcement (MANG), nor a capital or financing update (CAP). Given the nature of the filing as a current report announcing a corporate event without detailed financial data, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other categories.
2017-04-17 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 3, 2017, reporting the issuance of a press release announcing financial results for the period ended December 31, 2016. The text explicitly states that the press release is attached as Exhibit 99.1 and incorporated by reference. The document itself does not contain detailed financial statements or substantive financial data but rather serves as a notification of the press release. The length of the document is 3116 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of a report (the press release) rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement and does not fit other specific categories like Earnings Release (ER) or Annual Report (10-K).
2017-04-03 English
FORM 10-K
Annual Report FY 2016
2017-04-03 English
NT 10-K
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25, which is a Notification of Late Filing submitted to the SEC. It specifically states that the company's Annual Report on Form 10-K for the period ended December 31, 2016 could not be filed on time and explains the reasons for the delay. The document does not contain the actual 10-K report or financial statements but is a notification about the late filing of the 10-K. According to the classification rules, such a notification is a Regulatory Filing (RNS) because it is a compliance document related to the filing process and does not contain substantive financial data or the report itself.
2017-04-03 English
424B3
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated March 22, 2017, containing a press release about Moleculin Biotech receiving Orphan Drug Designation for its drug Annamycin. The content includes a description of the drug, the designation, and forward-looking statements. There are no financial statements or detailed financial data presented. The document primarily serves as a regulatory announcement of a significant event (FDA orphan drug designation) rather than a financial report, earnings release, or management discussion. It also includes a prospectus supplement related to a securities offering, indicating capital raising activity. However, the main body is a regulatory filing reporting a material event. Given the nature of the filing and the absence of financial data or detailed financial analysis, the most appropriate classification is Regulatory Filings (RNS).
2017-03-23 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content specifically mentions the issuance of a press release about the FDA granting Orphan Drug Designation to the company's lead candidate. The document includes the press release as an exhibit but does not contain financial statements or detailed financial data. The length is only 2560 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication of quarterly or annual financial results, management discussion, or audit information. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2017-03-22 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.